Reports › ALAB › 10-Q FY2026

SEC filings, compared

What changed in Astera Labs,'s 10-Q for the quarter ended June 30, 2026

Compared with the 10-Q for the quarter ended June 30, 2025. Part I, Item 2 and Part II, Item 1A analysed; every summary checked against the quoted filing text.

Registrant: Astera Labs, Inc. · ALAB
This filing: 0001736297-26-000035 ↗ · filed Aug 5, 2026
Compared with: 0001736297-25-000098 ↗ · filed Aug 6, 2025
Processed: Sep 20, 2026 UTC · parser-v5 · classify-v4 · select-v1

Research tool. Describes what filings say. Not investment advice. Verify independently. Read the cited paragraph before relying on it.

How a report is made

41 material changes among 65 changed paragraphs

13 shown by default across the three sections below; each section's "Show all" reaches the rest, in filing order.

Numbers from XBRL

Each figure is the one the filing itself tagged, taken from the filing that reported it. Not written by a model.

Concept	FY2026	FY2025	Change (our arithmetic)
Revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	392,400,000USD · Apr 1, 2026 to Jun 30, 2026	191,925,000USD · Apr 1, 2025 to Jun 30, 2025	+200,475,000+104.5%
Net income or lossus-gaap:NetIncomeLoss	153,088,000USD · Apr 1, 2026 to Jun 30, 2026	51,219,000USD · Apr 1, 2025 to Jun 30, 2025	+101,869,000+198.9%
Cash and cash equivalentsus-gaap:CashAndCashEquivalentsAtCarryingValue	111,453,000USD · at Jun 30, 2026	162,328,000USD · at Jun 30, 2025	−50,875,000−31.3%
Net cash from operating activitiesus-gaap:NetCashProvidedByUsedInOperatingActivities	162,276,000USD · Jan 1, 2026 to Jun 30, 2026	145,870,000USD · Jan 1, 2025 to Jun 30, 2025	+16,406,000+11.2%

Values as tagged in the filing's inline XBRL, resolved by accession rather than by period matching. When a value is not tagged, we show that instead of estimating it. FY2026: 0001736297-26-000035 · FY2025: 0001736297-25-000098

What the company says for the first time

Paragraphs with no counterpart in the prior filing.

3 material additions

Part I, Item 2 · MD&A

3 of 3 shown · In filing order, too few to rank

01AddedPart I, Item 2 › Summary of Financial Highlights

Summary · quote-checked

Added disclosure that gross margin decreased by 250 basis points to 73.3% for the three months ended June 30, 2026.

The new MD&A paragraph adds a substantive margin result and direction of change, rather than merely rolling forward a period or figure.

Filing text · FY2025 10-Q · filed Aug 6, 2025

No corresponding language in the FY2025 10-Q.

Filing text · FY2026 10-Q · filed Aug 5, 2026

[added] Gross margin decreased by 250 basis points ("bps") to 73.3% for the three months ended June 30, 2026, compared to 75.8% for the same period in 2025.

Cite this change

"Gross margin decreased by 250 basis points ("bps") to 73.3% for the three months ended June 30, 2026, compared to 75.8% for the same period in 2025."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

02AddedPart I, Item 2 › Summary of Financial Highlights

Summary · quote-checked

Added an MD&A statement reporting an 80-basis-point gross-margin decline for the six months ended June 30, 2026.

The new paragraph states a changed financial result and direction, not merely a period roll-forward; it adds substantive information about gross-margin performance.

Filing text · FY2025 10-Q · filed Aug 6, 2025

No corresponding language in the FY2025 10-Q.

Filing text · FY2026 10-Q · filed Aug 5, 2026

[added] Gross margin decreased by 80 bps to 74.6% for the six months ended June 30, 2026 compared to 75.4% for the same period in 2025.

Cite this change

"Gross margin decreased by 80 bps to 74.6% for the six months ended June 30, 2026 compared to 75.4% for the same period in 2025."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

03AddedPart I, Item 2 › Non-GAAP Operating Income and Non-GAAP Operating Margin

Summary · quote-checked

Added a definition of acquisition-related costs, including incremental professional fees incurred to effect a business combination.

The new paragraph introduces a distinct non-GAAP cost category and identifies business-combination-related expenses, changing the disclosed composition of adjusted operating measures.

Filing text · FY2025 10-Q · filed Aug 6, 2025

No corresponding language in the FY2025 10-Q.

Filing text · FY2026 10-Q · filed Aug 5, 2026

[added] (1) Acquisition-related costs include certain incremental expenses incurred to effect a business combination such as third-party costs: advisory, legal, accounting, valuation, and other professional fees.

Cite this change

"(1) Acquisition-related costs include certain incremental expenses incurred to effect a business combination such as third-party costs: advisory, legal, accounting, valuation, and other professional fees."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

What the company no longer says

Paragraphs of the prior filing that this filing dropped. Only last year's text can show these.

9 material removals

Part I, Item 2 · MD&A

5 of 9 shown · Ordered by the model, quote-checked

01RemovedPart I, Item 2 › Financing Activities

Summary · quote-checked

The financing activities paragraph describing IPO proceeds, stock-option proceeds, tax withholding, and deferred offering costs was removed.

Removing this paragraph eliminates disclosure about financing sources, liquidity-related cash uses, and obligations associated with the IPO and equity awards.

Why the model ranked it here

A client should read this because removing the financing narrative obscures the company’s disclosed sources of cash, liquidity uses, and equity-related obligations.

Filing text · FY2025 10-Q · filed Aug 6, 2025

[removed] Net cash provided by financing activities for the six months ended June 30, 2024 of $649.2 million was the result of $672.2 million in proceeds from our IPO, net of underwriting discounts and commissions, and $1.9 million in proceeds from exercises of stock options net of repurchases. This was partially offset by $20.1 million in tax withholding related to net share settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO, and $4.8 million in payments of deferred offering costs.

Filing text · FY2026 10-Q · filed Aug 5, 2026

No corresponding language in the FY2026 10-Q.

Cite this change

"Net cash provided by financing activities for the six months ended June 30, 2024 of $649.2 million was the result of $672.2 million in proceeds from our IPO, net of underwriting discounts and commissions, and $1.9 million in proceeds from exercises of stock options net of repurchases."

Astera Labs,, Form 10-Q for FY2025, Part I, Item 2, accession 0001736297-25-000098, filed 6 August 2025.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629725000098/alab-20250630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

02RemovedPart I, Item 2 › Investing Activities

Summary · quote-checked

The current report removes the paragraph explaining net cash used in investing activities and its marketable securities and property and equipment drivers.

Removing a cash-flow results narrative eliminates disclosure about investing cash usage and its stated sources and offsets; this is more than a date or period roll-forward.

Why the model ranked it here

A client should read this because removing the investing narrative obscures the company’s disclosed cash usage and the marketable securities and property investments driving it.

Filing text · FY2025 10-Q · filed Aug 6, 2025

[removed] Net cash used in investing activities for the six months ended June 30, 2024 of $306.7 million was the result of $345.8 million in purchases of marketable securities and $2.1 million in purchases of property and equipment. This was partially offset by $41.1 million in proceeds from sales and maturities of marketable securities.

Filing text · FY2026 10-Q · filed Aug 5, 2026

No corresponding language in the FY2026 10-Q.

Cite this change

"Net cash used in investing activities for the six months ended June 30, 2024 of $306.7 million was the result of $345.8 million in purchases of marketable securities and $2.1 million in purchases of property and equipment."

Astera Labs,, Form 10-Q for FY2025, Part I, Item 2, accession 0001736297-25-000098, filed 6 August 2025.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629725000098/alab-20250630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

03RemovedPart I, Item 2 › Income Tax (Benefit) Provision

Summary · quote-checked

The current filing removes an MD&A explanation of the decrease in income tax benefits and its stated drivers.

The removed paragraph contained a substantive results narrative, including the direction of change, amount, percentage and explanations involving revenue and capitalized research and development expenditures.

Why the model ranked it here

A client should read this because removing the tax-benefit explanation eliminates management’s stated reasons for a material change in tax benefits.

Filing text · FY2025 10-Q · filed Aug 6, 2025

[removed] The benefits from income tax decreased $6.0 million, or 91%, for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to an increase in revenue and capitalized research and development expenditures in accordance with Section 174 of the Internal Revenue Code.

Filing text · FY2026 10-Q · filed Aug 5, 2026

No corresponding language in the FY2026 10-Q.

Cite this change

"The benefits from income tax decreased $6.0 million, or 91%, for the three months ended June 30, 2025, compared to the same period in 2024, primarily due to an increase in revenue and capitalized research and development expenditures in accordance with Section 174 of the Internal Revenue Code."

Astera Labs,, Form 10-Q for FY2025, Part I, Item 2, accession 0001736297-25-000098, filed 6 August 2025.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629725000098/alab-20250630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

04RemovedPart I, Item 2 › Income Tax (Benefit) Provision

Summary · quote-checked

Removed an explanation of tax provision effects involving the foreign derived intangible income deduction, research and development credits, and capitalized expenditures.

The removed text drops stated drivers of the income tax benefit provision, including offsets, so the MD&A explanation is substantively different.

Why the model ranked it here

A client should read this because removing the tax-provision discussion obscures the deductions, credits, and capitalized expenditures affecting the company’s tax results.

Filing text · FY2025 10-Q · filed Aug 6, 2025

The benefit from income tax increased $16.7 million, or 276%, for the six months ended June 30, 2025, compared to the same period in 2024, primarily due to an increase in benefits from the excess tax benefits related to equity compensation, [removed] the foreign derived intangible income deduction, and the U.S. research and development credits, partially offset by capitalized research and development expenditures in accordance with Section 174 of the Internal Revenue Code.

Filing text · FY2026 10-Q · filed Aug 5, 2026

No corresponding language in the FY2026 10-Q.

Cite this change

"the foreign derived intangible income deduction, and the U.S. research and development credits, partially offset by capitalized research and development expenditures in accordance with Section 174 of the Internal Revenue Code."

Astera Labs,, Form 10-Q for FY2025, Part I, Item 2, accession 0001736297-25-000098, filed 6 August 2025.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629725000098/alab-20250630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

05RemovedPart I, Item 2 › Non-GAAP Gross Profit and Non-GAAP Gross Margin

Summary · quote-checked

A disclosure of stock-based compensation tied to RSU vesting and the IPO liquidity event was removed.

The removed paragraph describes a specific compensation obligation and IPO-related vesting event, not a date roll-forward, formatting change, or recurring list item.

Filing text · FY2025 10-Q · filed Aug 6, 2025

[removed] (1) Stock-based compensation expense recognized in connection with the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

Filing text · FY2026 10-Q · filed Aug 5, 2026

No corresponding language in the FY2026 10-Q.

Cite this change

"(1) Stock-based compensation expense recognized in connection with the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO."

Astera Labs,, Form 10-Q for FY2025, Part I, Item 2, accession 0001736297-25-000098, filed 6 August 2025.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629725000098/alab-20250630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

Show all 9 in Part I, Item 2 (4 more, in filing order)

What the company says differently

Paragraphs that changed between the two filings, shown as a word diff.

29 material changes

Part I, Item 2 · MD&A

5 of 29 shown · Ordered by the model, quote-checked

01ChangedPart I, Item 2 › Liquidity and Capital Resources

Summary · quote-checked

The liquidity discussion changed from prior operating losses and an accumulated deficit to positive operating cash flow and retained earnings.

Although the periods and cash-flow figure roll forward, the statement changes from accumulated losses to retained earnings, altering the disclosed financial condition and liquidity context.

Why the model ranked it here

The liquidity discussion changes from an accumulated deficit and history of operating losses to retained earnings and positive operating cash flow, materially altering the company’s disclosed financial condition.

Filing text · FY2025 10-Q · filed Aug 6, 2025

~~[removed] While we have generated $145.9~~ million in cash flow from operating activities for the six months ended June 30, ~~[removed] 2025, in prior years we generated significant losses from operations and negative cash flows from operating activities as reflected in our accumulated deficit of $125.8~~ million as of June 30, ~~[removed] 2025.~~ We believe that our current cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next 12 months and beyond. Our future capital requirements, however, will depend on many factors, including our growth rate, the timing and extent of our sales and marketing and research and development expenditures, capital expenditures for production equipment, the continuing market acceptance of our products, and the use of cash to fund potential mergers or acquisitions. In the event that additional financing is required from outside sources, we may seek to raise additional funds through equity, equity-linked arrangements, and debt. If we are unable to raise additional capital when desired and at reasonable rates, our business, results of operations, and financial condition could be adversely affected.

Filing text · FY2026 10-Q · filed Aug 5, 2026

[added] We generated $162.3 million in cash flow from operating activities for the six months ended June 30, [added] 2026 and retained earnings of $243.7 million as of June 30, [added] 2026. We believe that our current cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next 12 months and beyond. Our future capital requirements, however, will depend on many factors, including our growth rate, the timing and extent of our sales and marketing and research and development expenditures, capital expenditures for production equipment, the continuing market acceptance of our products, and the use of cash to fund potential mergers or acquisitions. In the event that additional financing is required from outside sources, we may seek to raise additional funds through equity, equity-linked arrangements, and debt. If we are unable to raise additional capital when desired and at reasonable rates, our business, results of operations, and financial condition could be adversely affected.

Cite this change

"We generated $162.3 million in cash flow from operating activities for the six months ended June 30, 2026 and retained earnings of $243.7 million as of June 30, 2026."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

02ChangedPart I, Item 2 › Change in Cash Flows from Operating Activities

Summary · quote-checked

Operating cash flow increased, with substantially different amounts and drivers, including changes in net income, non-cash charges, inventory, receivables and other operating assets and liabilities.

The MD&A changes the cash-flow result and materially revises the stated drivers, including newly identified warrants contra revenue and significantly different working-capital effects; this is more than a period roll-forward.

Why the model ranked it here

Operating cash flow growth is now accompanied by a substantially unfavorable working-capital effect, changing the explanation of how cash is being generated.

Filing text · FY2025 10-Q · filed Aug 6, 2025

Net cash provided by operating activities for the six months ended June 30, ~~[removed] 2025 of~~ $145.9 million [removed] resulted primarily from a net income of $83.0 million and non-cash charges of $80.3 million primarily related to $77.9 million in stock-based compensation expense, partially offset by cash used in operating assets and liabilities of $17.5 million. Cash used in operating assets and ~~[removed] liabilities during the period was primarily from a $18.5~~ million increase in ~~[removed] prepaid expenses and other assets primarily related to tax receivable and accrued interest receivable on short-term investments, a $14.6~~ million increase in ~~[removed] inventory primarily due to build up for anticipated demand, a $2.0 million decrease~~ in operating ~~[removed] lease liability, and a $1.6 million decrease in accrued expenses and other liabilities primarily~~ due to ~~[removed] accrued customer deposits~~ and the timing of [removed] payments. The net cash flow used in operating assets and liabilities was partially offset by an increase of $14.5 million in accounts receivable due to higher product sales and the timing of customer payments and a $4.6 million increase in accounts payable ~~[removed] mainly~~ due to the timing of payments.

Filing text · FY2026 10-Q · filed Aug 5, 2026

Net cash provided by operating activities [added] was $162.3 million for the six months ended June 30, [added] 2026, compared to $145.9 million [added] for the comparable period in 2025. The $16.4 million increase in operating cash inflows was a result of a $150.4 million increase in net income, higher non-cash charges of $50.1 million, partially offset by an unfavorable change of $184.0 million from changes in operating assets and [added] liabilities. The higher non-cash charges of $50.1 million were primarily due to a $35.0 million increase in [added] stock-based compensation expense, a $10.2 million increase in warrants contra revenue, and a $5.1 million increase in [added] depreciation and amortization. The unfavorable change of $184.0 million in operating [added] assets and liabilities was predominantly attributable to (i) a $124.0 million unfavorable change in accounts receivable due to [added] higher product sales and the timing of [added] customer payments, (ii) a $38.6 million unfavorable change in inventory primarily resulting from per-unit inventory costs and inventory build up to support anticipated demand, and (iii) a $22.9 million unfavorable change in the prepaid expenses and other assets. These unfavorable changes were partially offset by a $1.4 million favorable change in accounts payable [added] and accrued other liabilities primarily due to the timing of payments.

Cite this change

"The $16.4 million increase in operating cash inflows was a result of a $150.4 million increase in net income, higher non-cash charges of $50.1 million, partially offset by an unfavorable change of $184.0 million from changes in operating assets and liabilities."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

03ChangedPart I, Item 2 › Change in Cash Flows from Investing Activities

Summary · quote-checked

Investing cash use increased, with changed amounts and drivers including business-acquisition payments, marketable securities activity, and property purchases.

The paragraph changes the reported cash-flow amount and substantive explanations, adding acquisition payments and changing the stated drivers and magnitudes of investing cash use.

Why the model ranked it here

Investing cash use increased and now includes payments for business acquisitions, indicating a materially different deployment of cash.

Filing text · FY2025 10-Q · filed Aug 6, 2025

Net cash used in investing activities for the six months ended June 30, ~~[removed] 2025 of~~ $67.6 million ~~[removed] was the result of $404.7 million in purchases~~ of marketable ~~[removed] securities and $6.6 million~~ in purchases of property and ~~[removed] equipment,~~ partially offset by ~~[removed] $343.6 million in proceeds from sales and maturities~~ of marketable securities.

Filing text · FY2026 10-Q · filed Aug 5, 2026

Net cash used in investing activities [added] was $225.6 million for the six months ended June 30, [added] 2026, compared to $67.6 million [added] for the comparable period in 2025. The increase in cash used in investing activities of $157.9 million was primarily due to a $109.7 million decrease in proceeds from sales and maturities of marketable [added] securities, a $69.2 million increase in payments related to business acquisitions, and a $21.5 million increase in purchases of property and [added] equipment. These increases were partially offset by [added] a $45.0 million decrease in purchases of marketable securities.

Cite this change

"Net cash used in investing activities was $225.6 million for the six months ended June 30, 2026, compared to $67.6 million for the comparable period in 2025. The increase in cash used in investing activities of $157.9 million was primarily due to a $109.7 million decrease in proceeds from sales and maturities of marketable securities, a $69.2 million increase in payments related to business acquisitions, and a $21.5 million increase in purchases of property and equipment. These increases were partially offset by a $45.0 million decrease in purchases of marketable securities."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

04ChangedPart I, Item 2 › Non-GAAP Net Income

Summary · quote-checked

The paragraph newly states that a valuation allowance is maintained for GAAP purposes and changes the basis from profitability to cumulative tax profits.

The GAAP valuation allowance disclosure changes the stated accounting position and obligation; updated periods and tax rates do not override that substantive change.

Why the model ranked it here

The company newly states that it maintains a valuation allowance for GAAP purposes, changing the disclosed tax accounting position.

Filing text · FY2025 10-Q · filed Aug 6, 2025

(3) Income tax effect is calculated based on the tax laws in the jurisdictions in which we operate and is calculated to exclude the impact of stock-based compensation expense and one-off discrete tax adjustments that are unrelated to our core operating performance. ~~[removed] We~~ no longer maintain valuation allowance for non-GAAP purposes due to our ~~[removed] profitability~~ on a non-GAAP basis. For the three months ended June 30, ~~[removed] 2025 and 2024,~~ the non-GAAP tax rate was approximately ~~[removed] 9% and 23%,~~ respectively. For the six months ended June 30, ~~[removed] 2025 and 2024,~~ the non-GAAP tax rate was approximately ~~[removed] 8% and 23%,~~ respectively.

Filing text · FY2026 10-Q · filed Aug 5, 2026

(3) Income tax effect is calculated based on the tax laws in the jurisdictions in which we operate and is calculated to exclude the impact of [added] non-cash stock-based compensation expense and one-off discrete tax adjustments that are unrelated to our core operating performance. [added] While we maintain a valuation allowance for GAAP purposes, we no longer maintain valuation allowance for non-GAAP purposes due to our [added] cumulative tax profits on a non-GAAP basis. For the three months ended June 30, [added] 2026 and 2025, the non-GAAP tax rate was approximately [added] 12% and 9%, respectively. For the six months ended June 30, [added] 2026 and 2025, the non-GAAP tax rate was approximately [added] 11% and 8%, respectively.

Cite this change

"While we maintain a valuation allowance for GAAP purposes, we no longer maintain valuation allowance for non-GAAP purposes due to our cumulative tax profits on a non-GAAP basis."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

05ChangedPart I, Item 2 › Overview

Summary · quote-checked

Updated revenue figures and periods, while removing disclosures about product investments and the absence of annual profitability.

The paragraph no longer states that significant product investments were made or that annual profitability had not been achieved, changing substantive MD&A disclosure beyond routine period roll-forward.

Why the model ranked it here

The updated overview removes the prior statement that annual profitability had not been achieved and omits discussion of significant product investments, changing the stated business outlook and context.

Filing text · FY2025 10-Q · filed Aug 6, 2025

Since our inception, we have created and commercialized first-to-market PCIe, Ethernet, and CXL products. We have become a trusted partner and a proven supplier to our hyperscaler and system OEM customers. We have experienced strong growth since the commercial launch of Aries in 2020. Our revenue grew from $34.8 million in 2021, $79.9 million in 2022, ~~[removed] and $115.8~~ million in ~~[removed] 2023 to $396.3~~ million in ~~[removed] 2024.~~ Our revenue was ~~[removed] $351.4~~ million for the six months ended June 30, ~~[removed] 2025,~~ driven by a sizable increase in demand for our products.[removed] We have made significant investments in the design and development of new products and platform enhancements. Although we have recently recorded quarterly net income, we have not yet achieved profitability on an annual basis.

Filing text · FY2026 10-Q · filed Aug 5, 2026

Since our inception, we have created and commercialized first-to-market PCIe, Ethernet, and CXL products. We have become a trusted partner and a proven supplier to our hyperscaler and system OEM customers. We have experienced strong growth since the commercial launch of Aries in 2020. Our revenue grew from $34.8 million in 2021, $79.9 million in 2022, [added] $115.8 million in 2023, and $396.3 million in [added] 2024, to $852.5 million in [added] 2025. Our revenue was [added] $700.8 million for the six months ended June 30, [added] 2026, driven by a sizable increase in demand for our products.

Cite this change

"Our revenue was $700.8 million for the six months ended June 30, 2026, driven by a sizable increase in demand for our products."

Astera Labs,, Form 10-Q for FY2026, Part I, Item 2, accession 0001736297-26-000035, filed 5 August 2026.

Filing: https://www.sec.gov/Archives/edgar/data/1736297/000173629726000035/alab-20260630.htm

Comparison: https://yearover.com/reports/alab/0001736297-26-000035?ref=quote

Show all 29 in Part I, Item 2 (24 more, in filing order)

What the company reported as changed this quarter

We have not parsed the annual report this quarter's risk factors refers to, so we cannot tell whether it restates the section or reports changes to it. Nothing is compared until we can.

Part II, Item 1A · Risk Factors

Get this when ALAB files next

At most one email a day, and only when a company we cover files. Over the last twelve months that averaged about 5 days a month, unevenly: 12 in the busiest month and 1 in the quietest. You confirm by email first; nothing is sent until you do.